Sutro Biopharma Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sutro Biopharma stock.
View analyst ratings for Sutro Biopharma or view top-rated stocks.

Wall Street analysts have given Sutro Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sutro Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Sutro Biopharma saw a drop in short interest in January. As of January 29th, there was short interest totaling 916,000 shares, a drop of 19.6% from the January 14th total of 1,140,000 shares. Based on an average trading volume of 648,100 shares, the short-interest ratio is currently 1.4 days.
View Sutro Biopharma's Short Interest.

Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Sutro Biopharma.

Sutro Biopharma, Inc. (NASDAQ:STRO) announced its quarterly earnings results on Thursday, November, 5th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.96. The company had revenue of $17.82 million for the quarter, compared to analysts' expectations of $8.71 million. Sutro Biopharma had a net margin of 27.60% and a negative trailing twelve-month return on equity of 41.86%.
View Sutro Biopharma's earnings history.

Sutro Biopharma's stock was trading at $8.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STRO stock has increased by 160.3% and is now trading at $21.11.
View which stocks have been most impacted by COVID-19.

7 analysts have issued 12-month price objectives for Sutro Biopharma's stock. Their forecasts range from $17.00 to $37.00. On average, they expect Sutro Biopharma's stock price to reach $23.33 in the next year. This suggests a possible upside of 10.5% from the stock's current price.
View analysts' price targets for Sutro Biopharma or view top-rated stocks among Wall Street analysts.

11 employees have rated Sutro Biopharma CEO William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among Sutro Biopharma's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Sutro Biopharma include Revolution Medicines (RVMD), NantKwest (NK), Editas Medicine (EDIT), NanoString Technologies (NSTG), Sorrento Therapeutics (SRNE), Kymera Therapeutics (KYMR), Bavarian Nordic A/S (BVNRY), AlloVir (ALVR), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), bluebird bio (BLUE), Scholar Rock (SRRK), C4 Therapeutics (CCCC), Translate Bio (TBIO) and Ocugen (OCGN).
View all of STRO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Pharmaceuticals (XERS) and AbbVie (ABBV).

(STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Sutro Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.04%), Frazier Management LLC (2.59%), FIL Ltd (1.93%), Avidity Partners Management LP (1.62%), Ikarian Capital LLC (1.59%) and Candriam Luxembourg S.C.A. (0.95%). Company insiders that own Sutro Biopharma stock include Arturo Md Molina, John Gordon Freund, Trevor Hallam and William J Newell.
View institutional ownership trends for Sutro Biopharma.

STRO stock was sold by a variety of institutional investors in the last quarter, including Endurant Capital Management LP, Barclays PLC, JPMorgan Chase & Co., and HighVista Strategies LLC. Company insiders that have sold Sutro Biopharma company stock in the last year include John Gordon Freund, and Trevor Hallam.
View insider buying and selling activity for Sutro Biopharma or view top insider-selling stocks.

STRO stock was bought by a variety of institutional investors in the last quarter, including Frazier Management LLC, BlackRock Inc., Avidity Partners Management LP, FIL Ltd, Candriam Luxembourg S.C.A., Orbimed Advisors LLC, Silverarc Capital Management LLC, and Opaleye Management Inc.. Company insiders that have bought Sutro Biopharma stock in the last two years include Arturo Md Molina, and William J Newell.
View insider buying and selling activity for Sutro Biopharma or or view top insider-buying stocks.

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STRO stock can currently be purchased for approximately $21.11.

Sutro Biopharma has a market capitalization of $814.93 million and generates $42.74 million in revenue each year. The company earns $-55,740,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis.

Sutro Biopharma employs 182 workers across the globe.

The official website for Sutro Biopharma is www.sutrobio.com.

Sutro Biopharma is headquartered at 310 Utah Avenue Suite 150, South San Francisco CA, 94080.

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412 or via email at [email protected]